Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot Consistency of Sinovac 23-Valent Pneumococcal Vaccine in Adults
NCT05731115Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sinovac 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Geometric Mean Concentration. Started Feb 2023; status: completed.
02
Drugs
Sinovac 23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT05731115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731115.